REFERENCES
- Quintas-Cardama A, Kantarjian H, O'brien S, Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25:3908–3914.
- Assouline S, Laneuville P, Gambacorti-Passerini C. Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia. N Engl J Med. 2006;354:2623–2624.
- Bergeron A, Réa D, Levy V, Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: A case series. Am J Respir Crit Care Med. 2007;176:814–818.
- Breccia M, Muscaritoli M, Cannella L, Stefanizzi C, Frustaci A, Alimena G. Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. Leuk Res. 2008;32:1626–1628.
- Ottmann O, Dombret H, Martinelli G, Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: Interim results of a phase 2 study. Blood. 2007;110:2309–2315.
- Kantarjian H, Pasquini R, Hamerschlak N, Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial. Blood. 2007;109:5143–5150.
- Talpaz M, Shah NP, Kantarjian H, Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531–2541.
- Henze G, Fengler R, Hartmann R. Chemotherapy for relapsed childhood acute lymphoblastic leukemia: Results of the BFM Study Group. Haematol Blood Transfus. 1994;36:374–379.
- Kwiatkowski RW, Lyamichev V, de Arruda M, Neri B. Clinical, genetic, and pharmacogenetic applications of the Invader assay. Mol Diagn. 1999;4:353–364.
- Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;11:1018–1029.
- Patey-Mariaud de Serre N, Reijasse D, Verkarre V, Chronic intestinal graft-versus-host disease: Clinical, histological and immunohistochemical analysis of 17 children. Bone Marrow Transplant. 2002;29:223–230.
- Akpek G, Chinratanalab W, Lee LA, Gastrointestinal involvement in chronic graft-versus-host disease: A clinicopathologic study. Biol Blood Marrow Transplant. 2003;9:46–51.
- Hensley ML, Ford JM. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol. 2003;40:21–25.
- Quintas-Cardama A, Han X, Kantarjian H, Cortes J. Dasatinib-induced platelet dysfunction. Blood (ASH Annual Meeting Abstracts). 2007;110:Abstract 2941.
- Piccaluga PP, Paolini S, Martinelli G. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Cancer. 2007;110:1178–1186.
- Schittenhelm MM, Shiraga S, Schroeder A, Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006;66:473–481.
- Texido G, Su IH, Mecklenbrauker I, The B-cell-specific Src-family kinase Blk is dispensable for B-cell development and activation. Mol Cell Biol. 2000;20:1227–1233.
- Blake SJ, Bruce Lyons A, Fraser CK, Hayball JD, Hughes TP. Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood. 2008;111:4415–4416.
- Schade AE, Schieven GL, Townsend R, Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood. 2008;111:1366–1377.